The mission of the Bioinformatics Shared Resource (BISR) is to guarantee the availability of comprehensive bioinformatics expertise to Sidney Kimmel Comprehensive Cancer Center (SKCCC) members involved in molecular cancer research, with special emphasis on techniques that generate high dimensional data. The BISR achieves this by partially funding the effort for several PhD-level investigators and related staff. BISR faculty have extensive experience in all aspects of high-throughput biological data analysis and computational modeling of biological systems. A critical development during the next funding period will be the emergence of large data sets comprising multiple omics data, including genomics (SNPs, allelic variation maps from high-throughput sequencing), epigenomics (methylation an-ays, bi-sulfite high-throughput sequencing), transcriptomics (microarrays and RNA-seq), proteomics (MS-MS and arrays), and metabolomics (MS and NMR). These data will require integration through annotations, both through genome sequence and using proteomic-based integration. Computational modeling of this data will play an increasingly important role, as the data could overwhelm mathematical analysis approaches that lack a biologically motivated model to place the data in context Pathway, network, and cellular systems analysis is expected to play a growing role in data interpretation, with systems biology and computational modeling emerging as critical capabilities for the BISR. This Core has been assembled with the breadth in expertise necessary for these developments. Lay: The Bioinformatics Resource provides comprehensive bioinformatics expertise to Cancer Center members involved in molecular cancer research, with special emphasis on techniques that generate high dimensional data. The BISR has several PhD-level investigators with extensive experience in all aspects of high-throughput biological data analysis and computational modeling of biological systems, together with support staff.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
4P30CA006973-53
Application #
9061630
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2016-05-01
Budget End
2017-04-30
Support Year
53
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Bharti, Santosh K; Mironchik, Yelena; Wildes, Flonne et al. (2018) Metabolic consequences of HIF silencing in a triple negative human breast cancer xenograft. Oncotarget 9:15326-15339
Jackson, Sadhana; Weingart, Jon; Nduom, Edjah K et al. (2018) The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids Barriers CNS 15:2
Dejea, Christine M; Fathi, Payam; Craig, John M et al. (2018) Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359:592-597
Gorin, Michael A; Rowe, Steven P; Patel, Hiten D et al. (2018) Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. J Urol 199:126-132
Jiang, Wei; Zhou, Xiaoyan; Li, Zengxia et al. (2018) Prolyl 4-hydroxylase 2 promotes B-cell lymphoma progression via hydroxylation of Carabin. Blood 131:1325-1336
Nagai, Kozo; Hou, Lihong; Li, Li et al. (2018) Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3. Oncotarget 9:32885-32899
Sturgeon, Kathleen M; Hackley, Renata; Fornash, Anna et al. (2018) Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema. Cancer 124:95-104
Baena-Del Valle, Javier A; Zheng, Qizhi; Esopi, David M et al. (2018) MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer. J Pathol 244:11-24
Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol 74:218-225
Zarif, Jelani C; Antonarakis, Emmanuel S (2018) Targeting ELK1: a wELKome addition to the prostate cancer armamentarium. AME Med J 3:

Showing the most recent 10 out of 2393 publications